Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Study of link between cell phone use and brain tumours inconclusive

The world's biggest investigation on possible links between cell phone use and brain tumours is inconclusive, according to a Canadian scientist who collaborated on the Interphone International Study Group. Jack Siemiatycki, a professor at the University of Montreal and an epidemiologist at the University of Montreal Hospital Research Center, says restricted access to participants compromised the validity of results of the study to be published in the May 18 International Journal of Epidemiology.

18 May 2010

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

18 May 2010

No clear evidence of a mobile phone and brain cancer link

Use of mobile phones has been under scrutiny for a while now with many claiming a link between mobile phone use and brain cancer. The mild radioactive waves generated from mobile phones have so far been poorly understood. There are no known mechanisms by which mobile phone radiation could cause cancer. Unlike x-rays, mobile phone radiation is non-ionising, and is too weak to break apart DNA, which is necessary to induce other cancers. However scientists do agree that this radiation might speed up a growing brain tumor.

17 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Halozyme Therapeutics announces delivery of notice of breach to Baxter Healthcare

Halozyme Therapeutics, Inc. today announced the delivery of a notice of breach to Baxter Healthcare Corporation due to Baxter's failure to provide HYLENEX (hyaluronidase human injection) in accordance with the terms of the parties' existing development and supply contracts.

17 May 2010

Carcinogenic potential of mobile phone use not clear cut

The most comprehensive international study to date on the association between mobile phone use and brain cancers has not shown a strong causal link between the two but research on their relationship needs to continue, Professor Bruce Armstrong from the School of Public Health says.

17 May 2010

No increase in risk of glioma or meningioma with use of mobile phones: INTERPHONE project

The International Journal of Epidemiology today published a combined data analysis from a multi national population-based case-control study of glioma and meningioma, the most common types of brain tumour. This is the first in a series of combined data analyses of head and neck tumours published as part of the internationally coordinated INTERPHONE project.

17 May 2010

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Protox Therapeutics Inc. a leader in the development of receptor targeted fusion proteins, today released financial results for the first quarter 2010, ended March 31, 2010. "The first quarter of 2010 marked significant achievements for the company, namely the announcement of positive top-line results from the TRIUMPH study and the subsequent completion of a five million dollar financing," said Dr. Fahar Merchant, President and CEO of Protox.

15 May 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Each day in the United States, 482 people are diagnosed with a brain tumor. For these 482 people, not many treatments exist. With the current treatments available, only 5% of those diagnosed with a Glioblastoma Multiform will survive more than 5 years. Only two new treatments have been approved by the FDA in the past two decades.

4 May 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

A new study links progression of a lethal type of brain tumor with reduced expression of more than 600 immune system genes, suggesting how complex the immune response is to the cancer and the resulting difficulty in targeting specific immune system proteins for treatment.

27 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Affymetrix, Inc. today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix® Research Services Laboratory (ARSL).

20 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

DNA modification can define early onset glioblastoma

A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.

16 Apr 2010

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

A study conducted by a collaborative team led by researchers from the University of Southern California (USC) may lead to better insight into the clinical outcome for some patients with a particularly aggressive type of brain cancer. The research may also provide a framework for development of targeted drug treatments.

16 Apr 2010

BeaconEquity.com releases investment report featuring Antigenics

BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

15 Apr 2010

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Scientists at Birmingham Children's Hospital and the Universities of Nottingham and Southampton have developed new guidelines that should help doctors to diagnose brain tumours in children more quickly.

15 Apr 2010

Brain Cancer News and Research

Further Reading

Study of link between cell phone use and brain tumours inconclusive

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

No clear evidence of a mobile phone and brain cancer link

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Halozyme Therapeutics announces delivery of notice of breach to Baxter Healthcare

Carcinogenic potential of mobile phone use not clear cut

No increase in risk of glioma or meningioma with use of mobile phones: INTERPHONE project

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

ImmunoCellular Therapeutics, UPENN sign research agreement

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

DNA modification can define early onset glioblastoma

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

BeaconEquity.com releases investment report featuring Antigenics

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News